The declining non-GAAP metrics confirm the business is under pressure while the Sun Pharma merger process continues. Traders should monitor for any updates on the merger timeline, regulatory approvals, or potential termination risks, as the deal is the primary catalyst for the stock.
Price Chart
Executive Summary
Organon furnished supplemental non-GAAP financial metrics for Q2 2026 via an 8-K, as it has suspended its earnings press release and conference call due to the pending merger with Sun Pharmaceutical Industries Limited. The non-GAAP metrics show a decline in Adjusted EBITDA, Adjusted Net Income, and Adjusted Diluted EPS compared to Q2 2025, reflecting ongoing operational headwinds and transition costs related to the pending merger.
Key Facts
- Organon suspended its quarterly earnings press release and conference call due to the pending merger with Sun Pharmaceutical Industries Limited.
- Q2 2026 GAAP Net Income was $108M, down from $145M in Q2 2025.
- Q2 2026 GAAP Diluted EPS was $0.40, down from $0.56 in Q2 2025.
- Q2 2026 Non-GAAP Adjusted Net Income was $230M, down from $261M in Q2 2025.
- Q2 2026 Non-GAAP Adjusted Diluted EPS was $0.85, down from $1.00 in Q2 2025.
- Q2 2026 Adjusted EBITDA was $461M, down from $522M in Q2 2025.
- Adjusted EBITDA margin fell to 29.6% in Q2 2026 from 32.7% in Q2 2025.
- GAAP Gross Profit was $847M in Q2 2026, down from $874M in Q2 2025.
- The filing includes $11M in costs related to the pending Sun Pharma transaction for both the three and six months ended June 30, 2026.
Financial Impact
Q2 2026 GAAP Net Income declined 25.5% YoY to $108M; Adjusted EBITDA declined 11.7% YoY to $461M; Adjusted Diluted EPS declined 15% YoY to $0.85.
Risk Factors
- Pending Sun Pharma merger may face regulatory or shareholder hurdles, creating deal risk.
- Continued operational weakness could pressure the deal valuation or terms.
- Suspension of earnings calls reduces transparency, increasing uncertainty around near-term performance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-089008 |
| Document: tm2621744d1_8k.htm | 0001104659-26-089008 |
| Document: 0001104659-26-089008-index-headers.html | 0001104659-26-089008 |
| Document: 0001104659-26-089008-index.html | 0001104659-26-089008 |
| Document: 0001104659-26-089008.txt | 0001104659-26-089008 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 9w ago | Institutional Cluster | $13.68 | awaiting T+60 | — | $13.74 (−0.44%) |
Jul 31, 2026 12w ago | 8-K | $13.55 $13.74 | ▼ −1.40% | ▲ +1.05% | $13.74 (−1.40%) |
Jul 17, 2026 14w ago | 8-K | $13.49 $13.77 | ▲ +2.08% | ▼ −2.76% | $13.74 (+1.85%) |
Jun 17, 2026 18w ago | DEFM14A | $13.42 $13.64 | ▲ +1.64% | ▼ −1.51% | $13.74 (+2.38%) |
Jun 11, 2026 19w ago | DEFA14A | $13.45 $13.78 | ▲ +2.45% | ▼ −1.94% | $13.74 (+2.16%) |
Jun 1, 2026 21w ago | PREM14A | $13.37 $13.75 | ▲ +2.84% | ▲ +1.87% | $13.74 (+2.81%) |
Apr 30, 2026 25w ago | DEFA14A | $13.25 $13.52 | ▲ +2.08% | ▼ −0.74% | $13.74 (+3.74%) |
Apr 30, 2026 25w ago | 8-K | $13.25 $13.52 | ▼ −2.08% | ▲ +0.74% | $13.74 (−3.74%) |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | $13.74 (+3.19%) |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | $13.74 (+3.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers